Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2023-01-30 Transaction in Own Shar…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX: Bilan semestriel du contrat de liquidité au 31 décembre 2022
Transaction in Own Shares Classification · 1% confidence The document is titled "Bilan semestriel du contrat de liquidité au 31 décembre 2022" (Semi-annual statement of the liquidity contract as of December 31, 2022). It details the status and transactions (purchases and sales) under a liquidity contract managed by TSAF for ABIVAX over the second half of 2022. This type of regular disclosure regarding market making or liquidity provision activities, especially when presented as a periodic statement (semi-annual), is a specific regulatory or contractual disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It is a specific financial/market activity report. Given the options, this specialized report on share trading activity related to market stability/liquidity provision does not fit perfectly into the main categories like 10-K, ER, or IR. It is a specific regulatory/contractual filing. Since it is a detailed report/statement and not just an announcement of a report, it is unlikely to be RPA or RNS unless no other category fits. The closest fit among the specialized categories is difficult, but it relates to capital structure/share activity, though not a direct issuance or buyback announcement (POS/SHA). In many regulatory contexts, detailed periodic disclosures that don't fit standard financial reports fall under general regulatory filings. However, since it details transactions and balances related to the company's shares under a specific agreement, it is a form of capital/financing related disclosure, but more specifically, it is a periodic disclosure of market activity. Given the options, and recognizing this as a specific, periodic disclosure related to market operations, it is best classified as a Regulatory Filing (RNS) as a catch-all for specialized, non-standard periodic reports, or potentially related to capital/share activity. Since it is a detailed statement and not just a brief announcement, RNS is the most appropriate fallback for this specific type of periodic contractual disclosure not covered by the primary financial reports.
2023-01-30 French
Abivax publie des nouvelles données sur le mécanisme d’action anti-inflammatoire d’obefazimod
Regulatory Filings Classification · 1% confidence The document is a press release dated January 5, 2023, announcing the publication of a scientific article detailing the anti-inflammatory mechanism of action of the drug candidate obefazimod in the journal 'Clinical and Translational Gastroenterology'. It discusses scientific findings, clinical trial context (Phase 3 ABTECT program for Ulcerative Colitis), and includes quotes from the CEO. This type of announcement, focusing on scientific validation and publication of research results, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general Regulatory Filings (RNS) or sometimes an Earnings Release (ER) if tied to quarterly results. However, since it is specifically announcing the publication of scientific data supporting the drug's mechanism, and it is not a formal financial report (10-K, IR, ER), nor a proxy/governance document, the most fitting category among the provided options for a detailed scientific/research update announcement is Investor Presentation (IP), as these often include deep dives into R&D data. Given the context of a press release announcing scientific validation, and lacking specific financial reporting headers, IP is the best fit for detailed scientific/pipeline updates aimed at investors. It is not a short announcement of a report being available (RPA/RNS), but the content itself is a detailed update.
2023-01-05 French
Abivax publishes novel data with respect to obefazimods anti-inflammatory mechanism of action
Environmental & Social Information Classification · 1% confidence The document is a press release dated January 5, 2023, announcing that Abivax has published novel scientific data regarding its drug candidate obefazimod in the peer-reviewed journal 'Clinical and Translational Gastroenterology'. The content focuses on scientific findings, mechanism of action, and updates on ongoing Phase 3 clinical trials (ABTECT program). This type of announcement, which disseminates specific scientific or clinical progress outside of mandatory periodic financial reports (like 10-K or IR), is typically classified as a general Regulatory Filing or News Release. Since it is not a formal Earnings Release (ER), Interim Report (IR), or a specific announcement like a Dividend (DIV) or Management Change (MANG), and it is a direct news item disseminated via EQS News, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for corporate news releases that don't fit elsewhere, especially when the core content is scientific publication news.
2023-01-05 English
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de voteNombre d'actions et droits de vote Novembre 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated December 21, 2022, from the French company ABIVAX. The core content explicitly details the 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights) as required by French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This type of mandatory periodic disclosure regarding share capital structure and voting rights is a specific regulatory filing, but it does not fit perfectly into the standard US SEC categories (10-K, ER, IR, etc.). Among the provided definitions, this relates most closely to changes in capital structure or significant share information. Since it is a mandatory disclosure about the total number of shares and voting rights, it is a specific type of capital/financing update or a general regulatory filing. Given the specific nature of reporting share capital and voting rights, it aligns best with 'Share Issue/Capital Change' (SHA) or, if viewed as a mandatory regulatory disclosure not covered elsewhere, 'Regulatory Filings' (RNS). However, the content is purely about the current count of shares and voting rights, which is a fundamental aspect of capital structure reporting, making SHA a strong candidate. Alternatively, since it is a mandatory disclosure of share structure, it could also be seen as a specific type of 'Major Shareholding Notification' (MRQ) if the context implies crossing a threshold, but here it seems to be a routine monthly update (dated 30/11/2022). Given the explicit focus on the total number of shares and voting rights, SHA (Share Issue/Capital Change) is the most appropriate fit for reporting the current state of the capital base, even if no immediate change is announced, as these reports often serve to confirm the base for future calculations. If SHA is interpreted strictly as an announcement of a *new* issue, then RNS (Regulatory Filings) is the fallback. Considering the French regulatory context where these monthly reports are standard, and the content directly addresses the capital base, I will classify it as SHA, as it pertains to the capital structure.
2022-12-21 French
Abivax reçoit l’approbation de la FDA pour le plan de développement pédiatrique avec obefazimod dans les MICI
Regulatory Filings Classification · 1% confidence The document is a press release dated December 20th, announcing that the FDA has approved the initial Pediatric Study Plan (iPSP) for obefazimod in treating Inflammatory Bowel Diseases (IBD) in children. It discusses ongoing Phase 3 clinical trials ('ABTECT program') and provides contact information and standard forward-looking statements typical of corporate news releases. This content is an announcement of a significant regulatory/clinical development, not a comprehensive annual report (10-K), a detailed interim report (IR), or a formal transcript (CT). It is a general corporate update regarding clinical progress and regulatory milestones. Since it is a formal announcement of a specific corporate event/update that doesn't fit the more specific categories like ER (Earnings Release) or DIV (Dividend Notice), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered elsewhere, or potentially 'LTR' (Legal Proceedings Report) if the focus was purely on regulatory interaction, but RNS is more appropriate for general positive news updates like this FDA interaction. Given the options, RNS (Regulatory Filings) is the most suitable general classification for a press release detailing a regulatory milestone (FDA iPSP approval) that isn't a core financial report or a specific insider/shareholder action.
2022-12-20 French
Abivax receives FDA agreement on pediatric development plan with obefazimod in IBD
Regulatory Filings Classification · 1% confidence The document is a press release dated December 20, 2022, announcing that Abivax received agreement from the FDA on its initial Pediatric Study Plan (iPSP) for obefazimod in IBD. It discusses ongoing Phase 3 clinical trials (ABTECT program) and provides company background and contact information. This type of announcement, detailing clinical trial progress, regulatory milestones, and business updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement of a key operational/clinical development milestone rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), and it is not explicitly about management changes (MANG), director dealings (DIRS), or dividends (DIV), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the content focuses heavily on clinical trial progress and FDA interaction, which often accompanies or precedes formal earnings reports, and it is distributed via EQS News, it functions as a significant corporate news announcement. However, since it is not a summary of financial results (ER) but rather a specific operational update, and it doesn't fit other specific categories, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although ER is sometimes used for major clinical updates. Given the context of a 'News Details' header and the nature of the announcement (FDA agreement on a study plan), it is a general regulatory/corporate news item. I will classify it as RNS as it is a broad regulatory announcement not covered by the more specific financial/governance codes.
2022-12-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.